The Experts below are selected from a list of 651 Experts worldwide ranked by ideXlab platform

Roi Cohen Kadosh - One of the best experts on this subject based on the ideXlab platform.

  • can transcranial electrical stimulation improve learning difficulties in atypical brain development a future possibility for cognitive training
    Developmental Cognitive Neuroscience, 2013
    Co-Authors: Beatrix Krause, Roi Cohen Kadosh
    Abstract:

    Learning difficulties in atypical brain development represent serious obstacles to an individual's future achievements and can have broad societal consequences. Cognitive training can improve learning impairments only to a certain degree. Recent evidence from normal and clinical adult populations suggests that transcranial electrical stimulation (TES), a portable, painless, inexpensive, and relatively safe Neuroenhancement tool, applied in conjunction with cognitive training can enhance cognitive intervention outcomes. This includes, for instance, numerical processing, language skills and response inhibition deficits commonly associated with profound learning difficulties and attention-deficit hyperactivity disorder (ADHD). The current review introduces the functional principles, current applications and promising results, and potential pitfalls of TES. Unfortunately, research in child populations is limited at present. We suggest that TES has considerable promise as a tool for increasing neuroplasticity in atypically developing children and may be an effective adjunct to cognitive training in clinical settings if it proves safe. The efficacy and both short- and long-term effects of TES on the developing brain need to be critically assessed before it can be recommended for clinical settings.

Lucia Ziccardi - One of the best experts on this subject based on the ideXlab platform.

  • Neuroenhancement and neuroprotection by oral solution citicoline in non arteritic ischemic optic neuropathy as a model of neurodegeneration a randomized pilot study
    PLOS ONE, 2019
    Co-Authors: Vincenzo Parisi, Lucilla Barbano, Antonio Di Renzo, Gianluca Coppola, Lucia Ziccardi
    Abstract:

    PURPOSE To evaluate whether treatment with Citicoline in oral solution (OS-Citicoline) would increase visual function, retinal ganglion cells (RGCs) function, and neural conduction along visual pathways (Neuroenhancement), and/or induce preservation of RGCs fibers' loss (neuroprotection) in non-arteritic ischemic optic neuropathy (NAION), a human model of neurodegeneration. METHODS Thirty-six patients with NAION and 20 age-matched controls were enrolled. Nineteen NAION patients received 500 mg/day of OS-Citicoline for a 6-month period followed by 3-month of wash-out (NC Group); 17 NAION patients were not treated (NN Group) from baseline to 9 months. In all subjects at baseline, and in NC and NN eyes at 6 and 9 months of follow-up, we assessed Visual Acuity (VA), Pattern Electroretinogram (PERG), Visual Evoked Potentials (VEP), retinal nerve fiber layer thickness (RNFL-T), and Humphrey 24-2 visual field mean deviation (HFA MD). Mean differences were statistically evaluated with ANOVA between Groups, and linear correlations were analysed with Pearson's test. RESULTS At 6 months, significant differences between groups for all parameters were observed (ANOVA, p<0.01). In NC eyes, VA increased, PERG responses increased, VEP recordings improved and were significantly correlated with increases in HFA MD (p<0.01), and RNFL-T was unmodified or improved. In contrast, in NN eyes, VA, PERG, VEP responses, RNFL-T, and HFA MD were further worsened. Significant differences were still present at 9-month follow-up in the NN Group and after 3 months of OS-Citicoline wash-out in NC eyes. CONCLUSIONS OS-Citicoline treatment induced Neuroenhancement (improvement in RGCs function and neural conduction along visual pathways related to improvement of visual field defects) and neuroprotection (unmodified or improved RNFL morphological condition) in a human model of NAION involving fast RGCs degeneration. TRIAL REGISTRATION ClinicalTrials.gov NCT03758118.

  • Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study.
    'Public Library of Science (PLoS)', 2019
    Co-Authors: Vincenzo Parisi, Lucilla Barbano, Antonio Di Renzo, Gianluca Coppola, Lucia Ziccardi
    Abstract:

    PurposeTo evaluate whether treatment with Citicoline in oral solution (OS-Citicoline) would increase visual function, retinal ganglion cells (RGCs) function, and neural conduction along visual pathways (Neuroenhancement), and/or induce preservation of RGCs fibers' loss (neuroprotection) in non-arteritic ischemic optic neuropathy (NAION), a human model of neurodegeneration.MethodsThirty-six patients with NAION and 20 age-matched controls were enrolled. Nineteen NAION patients received 500 mg/day of OS-Citicoline for a 6-month period followed by 3-month of wash-out (NC Group); 17 NAION patients were not treated (NN Group) from baseline to 9 months. In all subjects at baseline, and in NC and NN eyes at 6 and 9 months of follow-up, we assessed Visual Acuity (VA), Pattern Electroretinogram (PERG), Visual Evoked Potentials (VEP), retinal nerve fiber layer thickness (RNFL-T), and Humphrey 24-2 visual field mean deviation (HFA MD). Mean differences were statistically evaluated with ANOVA between Groups, and linear correlations were analysed with Pearson's test.ResultsAt 6 months, significant differences between groups for all parameters were observed (ANOVA, pConclusionsOS-Citicoline treatment induced Neuroenhancement (improvement in RGCs function and neural conduction along visual pathways related to improvement of visual field defects) and neuroprotection (unmodified or improved RNFL morphological condition) in a human model of NAION involving fast RGCs degeneration.Trial registrationClinicalTrials.gov NCT03758118

Beatrix Krause - One of the best experts on this subject based on the ideXlab platform.

  • Neuroenhancement of High-Level Cognition: Evidence for Homeostatic Constraints of Non-invasive Brain Stimulation
    Journal of Cognitive Enhancement, 2019
    Co-Authors: Beatrix Krause, Chung Yen Looi, Amar Sarkar, Martin Dresler, Roi Cohen Kadosh
    Abstract:

    Neuroenhancement aims to improve cognitive performance in typically and atypically functioning populations. However, it is currently debated whether it is also effective in exceptionally high-functioning individuals. Present theories suggest that homeostatic set points for learning and cortical plasticity limit the beneficial effects of Neuroenhancement. To examine this possibility, we used transcranial random noise stimulation (tRNS) to non-invasively stimulate bilateral dorsolateral prefrontal cortices (DLPFC) of the world champion in mental calculation, G.M. TRNS did not change G.M.’s calculation performance compared to sham stimulation on an exceptionally complex arithmetic task. However, a sample of mathematicians who were not calculation prodigies ( N  = 6) showed reduced accuracy on a complex multiplication task in response to tRNS, relative to sham. Our findings suggest that there may be an upper limit for cognitive enhancement and that further attempts to enhance performance using tRNS (at least with the current parameters) may impair optimal functioning. The discussion of potential negative effects of brain stimulation for cognitive enhancement is critical, as it may lead to unintended impairments in different subgroups of the population.

  • can transcranial electrical stimulation improve learning difficulties in atypical brain development a future possibility for cognitive training
    Developmental Cognitive Neuroscience, 2013
    Co-Authors: Beatrix Krause, Roi Cohen Kadosh
    Abstract:

    Learning difficulties in atypical brain development represent serious obstacles to an individual's future achievements and can have broad societal consequences. Cognitive training can improve learning impairments only to a certain degree. Recent evidence from normal and clinical adult populations suggests that transcranial electrical stimulation (TES), a portable, painless, inexpensive, and relatively safe Neuroenhancement tool, applied in conjunction with cognitive training can enhance cognitive intervention outcomes. This includes, for instance, numerical processing, language skills and response inhibition deficits commonly associated with profound learning difficulties and attention-deficit hyperactivity disorder (ADHD). The current review introduces the functional principles, current applications and promising results, and potential pitfalls of TES. Unfortunately, research in child populations is limited at present. We suggest that TES has considerable promise as a tool for increasing neuroplasticity in atypically developing children and may be an effective adjunct to cognitive training in clinical settings if it proves safe. The efficacy and both short- and long-term effects of TES on the developing brain need to be critically assessed before it can be recommended for clinical settings.

Wanja Wolff - One of the best experts on this subject based on the ideXlab platform.

  • Using Substances to Enhance Performance: A Psychology of Neuroenhancement
    'Frontiers Media SA', 2017
    Co-Authors: Ralf Brand, Wanja Wolff
    Abstract:

    Neuroenhancement (NE) is a behavior conceptualized as the use of a potentially psychoactive substance to enhance ones’ already proficient cognitive capacities. Depending on the specific definitions used, prevalence estimates vary greatly between very low 0.3% (for illicit substances) to astonishingly high 89% (for freely available lifestyle substances). These variations indicate that further research and more conceptual and theoretical clarification of the NE construct is dearly needed. The contributions of this research topic aim to do just that. Specific questions addressed are: How prevalent is NE behavior? How can NE research profit from the already more evolved field of social science research on doping in sports? How is NE perceived by the public? What psychological processes and variables play a role in the decision to neuroenhance? A wide array of methodological approaches is used to investigate these questions. The topics contributions range from theoretical to experimental accounts on NE, and they utilize a diverse set of methods ranging from qualitative to neuroscientific approaches. The research presented here represents a first step towards what we have labeled a psychological approach to NE. By addressing the questions above this research topic hopefully advances our understanding of NE behavior. As with every new field of research, new answers always prompt new questions. In light of what we know now about NE, we hope that the findings presented here will be pursued by other researchers in the future. Clearly, the endeavor to understand NE behavior has only just begun

  • Drugs as instruments: Describing and testing a behavioral approach to the study of Neuroenhancement
    Frontiers Media S.A., 2016
    Co-Authors: Ralf Brand, Wanja Wolff, Matthias Ziegler
    Abstract:

    Neuroenhancement (NE) is the non-medical use of psychoactive substances to produce a subjective enhancement in psychological functioning and experience. So far empirical investigations of individuals’ motivation for NE however have been hampered by the lack of theoretical foundation. This study aimed to apply drug instrumentalization theory to user motivation for NE. We argue that NE should be defined and analyzed from a behavioral perspective rather than in terms of the characteristics of substances used for NE. In the empirical study we explored user behavior by analyzing relationships between drug options (use over-the-counter products, prescription drugs, illicit drugs) and postulated drug instrumentalization goals (e.g. improved cognitive performance, counteracting fatigue, improved social interaction). Questionnaire data from 1,438 university students were subjected to exploratory and confirmatory factor analysis to address the question of whether analysis of drug instrumentalization should be based on the assumption that users are aiming to achieve a certain goal and choose their drug accordingly or whether NE behavior is more strongly rooted in a decision to try or use a certain drug option. We used factor mixture modeling to explore whether users could be separated into qualitatively different groups defined by a shared ‘goal × drug option’ configuration. Our results indicate, first, that individuals’ decisions about NE are eventually based on personal attitude to drug options (e.g. willingness to use an over-the-counter product but not to abuse prescription drugs) rather than motivated by desire to achieve a specific goal (e.g. fighting tiredness) for which different drug options might be tried. Second, data analyses suggested two qualitatively different classes of users. Both predominantly used over-the-counter products, but ‘neuroenhancers’ might be characterized by a higher propensity to instrumentalize over-the-counter products for virtually all investigated goals whereas ‘fatigue-fighters’ might be inclined to use over-the-counter products exclusively to fight fatigue. We believe that psychological investigations like these are essential, especially for designing programs to prevent risky behavior

  • Neuroenhancement and the strength model of self-control
    Frontiers in psychology, 2015
    Co-Authors: Chris Englert, Wanja Wolff
    Abstract:

    Neuroenhancement (NE), the use of substances as a means to enhance performance, has garnered considerable scientific attention of late. While ethical and epidemiological publications on the topic accumulate, there is a lack of theory-driven psychological research that aims at understanding psychological drivers of NE. In this perspective article we argue that self-control strength offers a promising theory-based approach to further understand and investigate NE behavior. Using the strength model of self-control, we derive two theory-driven perspectives on NE-self-control research. First, we propose that individual differences in state/trait self-control strength differentially affect NE behavior based on one's individual experience of NE use. Building upon this, we outline promising research questions that (will) further elucidate our understanding of NE based on the strength model's propositions. Second, we discuss evidence indicating that popular NE substances (like Methylphenidate) may counteract imminent losses of self-control strength. We outline how further research on NE's effects on the ego-depletion effect may further broaden our understanding of the strength model of self-control.

  • Subjective stressors in school and their relation to Neuroenhancement: a behavioral perspective on students' everyday life "doping"
    Substance Abuse Treatment Prevention and Policy, 2013
    Co-Authors: Wanja Wolff, Ralf Brand
    Abstract:

    Background: The use of psychoactive substances to neuroenhance cognitive performance is prevalent. Neuroenhancement (NE) in everyday life and doping in sport might rest on similar attitudinal representations, and both behaviors can be theoretically modeled by comparable means-to-end relations (substance-performance). A behavioral (not substance-based) definition of NE is proposed, with assumed functionality as its core component. It is empirically tested whether different NE variants (lifestyle drug, prescription drug, and illicit substance) can be regressed to school stressors. Findings: Participants were 519 students (25.8 ± 8.4 years old, 73.1% female). Logistic regressions indicate that a modified doping attitude scale can predict all three NE variants. Multiple NE substance abuse was frequent. Overwhelming demands in school were associated with lifestyle and prescription drug NE. Conclusions: Researchers should be sensitive for probable structural similarities between enhancement in everyday life and sport and systematically explore where findings from one domain can be adapted for the other. Policy makers should be aware that students might misperceive NE as an acceptable means of coping with stress in school, and help to form societal sensitivity for the topic of NE among our younger ones in general.

Vincenzo Parisi - One of the best experts on this subject based on the ideXlab platform.

  • Neuroenhancement and neuroprotection by oral solution citicoline in non arteritic ischemic optic neuropathy as a model of neurodegeneration a randomized pilot study
    PLOS ONE, 2019
    Co-Authors: Vincenzo Parisi, Lucilla Barbano, Antonio Di Renzo, Gianluca Coppola, Lucia Ziccardi
    Abstract:

    PURPOSE To evaluate whether treatment with Citicoline in oral solution (OS-Citicoline) would increase visual function, retinal ganglion cells (RGCs) function, and neural conduction along visual pathways (Neuroenhancement), and/or induce preservation of RGCs fibers' loss (neuroprotection) in non-arteritic ischemic optic neuropathy (NAION), a human model of neurodegeneration. METHODS Thirty-six patients with NAION and 20 age-matched controls were enrolled. Nineteen NAION patients received 500 mg/day of OS-Citicoline for a 6-month period followed by 3-month of wash-out (NC Group); 17 NAION patients were not treated (NN Group) from baseline to 9 months. In all subjects at baseline, and in NC and NN eyes at 6 and 9 months of follow-up, we assessed Visual Acuity (VA), Pattern Electroretinogram (PERG), Visual Evoked Potentials (VEP), retinal nerve fiber layer thickness (RNFL-T), and Humphrey 24-2 visual field mean deviation (HFA MD). Mean differences were statistically evaluated with ANOVA between Groups, and linear correlations were analysed with Pearson's test. RESULTS At 6 months, significant differences between groups for all parameters were observed (ANOVA, p<0.01). In NC eyes, VA increased, PERG responses increased, VEP recordings improved and were significantly correlated with increases in HFA MD (p<0.01), and RNFL-T was unmodified or improved. In contrast, in NN eyes, VA, PERG, VEP responses, RNFL-T, and HFA MD were further worsened. Significant differences were still present at 9-month follow-up in the NN Group and after 3 months of OS-Citicoline wash-out in NC eyes. CONCLUSIONS OS-Citicoline treatment induced Neuroenhancement (improvement in RGCs function and neural conduction along visual pathways related to improvement of visual field defects) and neuroprotection (unmodified or improved RNFL morphological condition) in a human model of NAION involving fast RGCs degeneration. TRIAL REGISTRATION ClinicalTrials.gov NCT03758118.

  • Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study.
    'Public Library of Science (PLoS)', 2019
    Co-Authors: Vincenzo Parisi, Lucilla Barbano, Antonio Di Renzo, Gianluca Coppola, Lucia Ziccardi
    Abstract:

    PurposeTo evaluate whether treatment with Citicoline in oral solution (OS-Citicoline) would increase visual function, retinal ganglion cells (RGCs) function, and neural conduction along visual pathways (Neuroenhancement), and/or induce preservation of RGCs fibers' loss (neuroprotection) in non-arteritic ischemic optic neuropathy (NAION), a human model of neurodegeneration.MethodsThirty-six patients with NAION and 20 age-matched controls were enrolled. Nineteen NAION patients received 500 mg/day of OS-Citicoline for a 6-month period followed by 3-month of wash-out (NC Group); 17 NAION patients were not treated (NN Group) from baseline to 9 months. In all subjects at baseline, and in NC and NN eyes at 6 and 9 months of follow-up, we assessed Visual Acuity (VA), Pattern Electroretinogram (PERG), Visual Evoked Potentials (VEP), retinal nerve fiber layer thickness (RNFL-T), and Humphrey 24-2 visual field mean deviation (HFA MD). Mean differences were statistically evaluated with ANOVA between Groups, and linear correlations were analysed with Pearson's test.ResultsAt 6 months, significant differences between groups for all parameters were observed (ANOVA, pConclusionsOS-Citicoline treatment induced Neuroenhancement (improvement in RGCs function and neural conduction along visual pathways related to improvement of visual field defects) and neuroprotection (unmodified or improved RNFL morphological condition) in a human model of NAION involving fast RGCs degeneration.Trial registrationClinicalTrials.gov NCT03758118